Shaun Foy

Shaun brings almost 20 years of experience in emerging healthcare companies as an entrepreneur, investor and advisor. Previously, Shaun served as CFO and a member of the board of directors of CRISPR Therapeutics, a company that he co-founded in 2013 that is focused on the therapeutic applications of the CRISPR/Cas9 technology. Prior to that he was a partner and one of the founding team members of Nomura Phase4 Ventures, a London-based venture capital group investing in emerging healthcare companies where he gained particular experience investing in cell and gene therapy companies. Prior to that, he worked with Nomura International’s healthcare corporate finance group advising emerging healthcare companies on M&A and capital raisings.

Shaun is a CFA® charterholder and holds an MSc in cell biology and immunology from the University of British Columbia in Canada.